| Similar Articles |
|---|
 |
Bio-IT World
August 2005 |
Project Summaries Summaries of candidates for Bio-IT World's "Best Practices 2005" projects.   |
Bio-IT World
August 2005
Kevin Davies |
Special Report: Bio-IT World Best Practices 2005 Each year, the Best Practices awards program spotlights examples of the most outstanding innovations, technologies, and practices in the drug discovery pipeline. |
Bio-IT World
August 15, 2005
Kevin Davies |
TGen's Discovery Pipeline in the Desert At the Translational Genomics Research Institute, researchers have developed an industrial-style informatics strategy and discovery infrastructure that has pinpointed some 25 disease genes in the past 24 months, many of which are pending identification. |
Bio-IT World
February 2006
Kevin Davies |
Curtain Opens on Life Sciences Expo Highlights of the upcoming Life Sciences Conference + Expo: Keynotes... Conference Tracks... Speakers... Educational workshops... etc. |
Bio-IT World
February 2007 |
Bio*IT World's Coming Attractions 2007 Bio-IT World Conference & Expo preview -- Meet the Keynotes... Oracle Users... Systems are Go... Candid Camera... A Vital IT Alliance... Next Generation Informatics... etc. |
Bio-IT World
August 15, 2005
John Russell |
Reasons for Optimism Submissions to the 2005 Bio-IT World Best Practices Awards Program included a description of a systems of hieroglyphic representations of proteins, a platform for integrative genomics, and a number of entries that saved man hours by utilizing client management tools. |
Bio-IT World
August 2005
Steven Withrow |
Harvard's Personalized Medicine Gateway With the right tools -- an enterprise-level, integrated infrastructure, for example -- an IT department can accelerate genetic and genomic science from discovery through clinical care. |
The Motley Fool
January 31, 2011
Brian Orelli |
Time to Buy Into Stem Cells? New developments bring this analyst a step closer to opening his wallet. |
Bio-IT World
January 21, 2005 |
Defining 'Integrative Genomics' Five experts from academia and industry discuss the burgeoning field of integrative genomics. |
Bio-IT World
October 9, 2002
Malorye Branca |
The Path to Personalized Medicine The tactics have changed, sometimes dramatically, but hints of the promise of pharmacogenomics are finally starting to trickle in from studies of asthma, cancer, and drug response. |
Bio-IT World
August 18, 2004
John Russell |
Special Report: 2004: A Best Practices Odyssey Grand Prize Winners: Drug Discovery & Development: Iconix Pharmaceuticals... IT Infrastructure & Informatics: Baylor College of Medicine, Department of Molecular and Cellular Biology Core Lab... etc. |
Bio-IT World
July 2005
Kevin Davies |
Medicine Gets Personal Touch More genomics-based drugs are moving into development with others, such as new cancer drugs showcasing on the clinical pharmacogenics scene as outlined in the Advances in Genomic Medicine program of a recent world conference. |
Bio-IT World
November 12, 2002
Michael Goldman |
A Virtual Pharmacopeia Computational modeling of disease pathways, organs --- even patients --- could transform drug discovery. Does salvation exist in silico? |
Bio-IT World
March 2006 |
Special Show Preview: It's Showtime! Highlights of the upcoming fifth annual Bio IT World conference: Decoding the Genome... The Six-Figure Sequence... E-Clinical Futures... etc. |
The Motley Fool
August 9, 2010
Jim Mueller |
3 Stocks to Play Biotech Three promising ideas for investing in this exciting area. |
Bio-IT World
September 2006
Mike May |
Working Out the Flow Better management of workflow issues in biotech and pharma could change fundamental aspects of these sciences in the near future. |
Bio-IT World
November 14, 2003
Malorye Branca |
Genomics Provides the Kick Inside New tools and business structures show signs of plumping early-stage pipelines. |
Chemistry World
July 2010
Hayley Birch |
Special Report: Health breakthroughs of the decade New discoveries have been made with cancer vaccines, genomics, statin drugs, allosteric modulators, and RNA interference during the last decade. |
Bio-IT World
March 17, 2004 |
Blood, Sweat, and Tissue Genomics Collaborative and Ardais take the lead in using IT to bring human tissue banking into the era of clinical genomics. |
Bio-IT World
Dec 2006/Jan 2007 |
Resolute in the New Year Industry leaders in areas from pharmacogenetics to cheminformatics found 2006 to be a year of important steps forward, but looked with even more anticipation to 2007: Allen D. Roses, SVP, Pharmacogenetics GlaxoSmithKline... etc. |
Bio-IT World
February 11, 2005
Robert M. Frederickson |
Genomics Drives New Crop of IVDs In vitro diagnostic microarrays are an important tool in oncology. The Affymetrix GeneChip System 3000Dx (GCS 3000Dx) was the first microarray instrument to be cleared by the FDA for IVD use. |
Bio-IT World
September 9, 2002
Malorye Branca |
The New, New Pharmacogenomics The field of pharmacogenomics proves valuable in the battle against toxicity and late-stage drug failure -- one of the pharmaceutical industry's biggest problems. |
Bio-IT World
May 2006
Kevin Davies |
Interpreting Genes and Genomes From microarrays to sequencing technology, molecular diagnostics to the interactome, this year's Bio-IT World Conference showcased exciting advances in genome technology applications, in which software analysis and data management play critical roles. |
Bio-IT World
November 12, 2002
James Golden |
The Business of Bioinformatics The industry has reached an interesting crossroads. As an academic branch of learning, bioinformatics remains mostly what it always was, a cross-disciplinary endeavor between computer science and molecular biology. But bioinformatics as a money-making proposition has different criteria for success. |
Bio-IT World
March 2006 |
Bio-IT World Bio-IT 50 The 50 companies profiled here have driven and continue to drive the future of biomedical research and drug discovery: Accelrys... Affymetrix.. Apple... Becton Dickinson... BlueArc... 454 Life Sciences... etc. |
Bio-IT World
August 15, 2005
Kevin Davies |
Pimp My Genome As costs plummet, the ability to rapidly synthesize and customize longer, more intricate fragments of genomic DNA opens up a plethora of applications in basic and applied biology. A commercial synthetic biology industry is beginning to take shape. |
CIO
October 15, 2001
Stephanie Overby |
Drug Companies on speed The marriage of IT and medical research may be just what traditional pharmaceutical companies need to survive in an increasingly competitive field. Learn how IT is bringing the pharmaceutical industry into the information age... |
Fast Company
November 2009
Stephanie Schomer |
Lost Dollars in Gene Research Billions of R&D dollars flowed to companies promising to cure our ills. Most of those companies are now dead or forgotten. |
Bio-IT World
Jul/Aug 2006
Kevin Davies |
Beyond the Last Chromosome About 700 attendees gathered Beyond Genome 2006, one of Cambridge Healthtech Institute's flagship conferences, to discuss the major technology trends in postgenomic biology, including systems biology, RNAi, proteomics, and personalized medicine. |
Bio-IT World
March 17, 2004 |
Pharma's Genomic Harvest How Pfizer plans to meet its goal of 20 new drug applications by 2006. |
The Motley Fool
December 22, 2009
Brian Orelli |
Pfizer Swings for the Fences A long shot, but at least it's cheap. Pfizer seems to have taken a particular liking to stem cells, having established a unit to study them last year |
Fast Company
September 2000
John Ellis |
The Secret of Life The mapping of the human genome, says Craig Venter, will change science, research, medicine, politics, health insurance, and the way biology looks at the last 3 billion years of evolution. And that's just the beginning. |
Bio-IT World
April 15, 2003
Malorye Branca |
Beyond the Blueprint How will the wealth of data emanating from the human genome and allied technologies impact research on health and disease? |
Bio-IT World
June 2006
Kevin Davies |
Broad Institute Releases GenePattern 2.0 Researchers at the Broad Institute have released an updated version of the popular GenePattern software suite. Further enhancements are said to be in the wings. |
Bio-IT World
November 2006
Kevin Davies |
Building a Bridge Over Pharma with IT More than 100 enthusiastic delegates bridging the full breadth of the drug development pipeline gathered recently for the second annual Bridging Pharma and IT conference. Here are some highlights. |
The Motley Fool
May 21, 2010
Brian Orelli |
And You Thought Biotech Was High-Risk, High-Reward Large clinical trials make cardiovascular drugs risky, but the rewards are there, too. |
Bio-IT World
December 15, 2003
Zachary Zimmerman |
Learning the Language of Systems Biology Geneticist par excellence David Botstein talks about his philosophy, science, his mission for integrative science, and what he deems a success for systems biology. |
Bio-IT World
July 14, 2004
Malorye A. Branca |
The Maven of Microarrays Affymetrix Research Institute's CEO, Stephen Fodor, discusses building a tech business without a blueprint |
Bio-IT World
January 13, 2003
John Dodge |
Talent Fuels Drug Pipeline in Swiss Time The functional genomics group has emerged as a critical link in the drug discovery chain at Novartis Pharmaceuticals Corp. While it employs a multidisciplinary approach to drug discovery, the four-year-old group's goals could not be simpler: Find novel drug targets. |
Bio-IT World
March 17, 2004
Zachary Zimmerman |
Testing Times for the FDA The FDA's pharmacogenomic guidance marks the beginning of a long process toward standardized tests. |
Bio-IT World
Jul/Aug 2006
John Russell |
Pharsight CRADA to Assist FDA with Modeling Initiative Pharsight will use FDA's feedback to further develop their server to meet drug-maker's analysis requirements, and further develop their visualization and collaboration tool to support FDA-sponsor interactions for the visualization and communication of model-based product profiles. |
Bio-IT World
February 2006
Juan Carlos Perez |
Google, Venter Mum on Collaboration Reports Google and the J. Craig Venter Institute are playing down highly publicized reports of a genetics research collaboration reported in the recently published The Google Story by David Vise and Mark Malseed. |
The Motley Fool
October 27, 2010
Ralph Casale |
Companion Diagnostics in Cancer Drug Development Diagnostic companies partnering with drug developers can make for an attractive investment segment. |
Bio-IT World
October 2005
Dennis A. Gilbert |
The DNA Sequencing Race: From Sprint to Marathon To create faster, cheaper, and better solutions for DNA analysis, we must remain committed to improving both current and new sequencing technologies. Research that just a short while ago might have been considered too complex, too expensive, or just inconceivable is now well within our grasp. |
Fast Company
November 2009
David H. Freedman |
The Gene Bubble: Why We Still Aren't Disease-Free When the human genome was first sequenced nearly a decade ago, the world lit up with talk about how new gene-specific drugs would help us cheat death. Well, the verdict is in: Keep eating those greens. |
The Motley Fool
February 16, 2010
Brian Orelli |
For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward. |
Bio-IT World
November 2005 |
Bridges and Boundaries in Drug Discovery Research Good communication, blurring cultural boundaries, and strong project governance may be as, if not more, important as sweeping technology solutions when it comes to converging discovery and IT and expediting drug development. |
Bio-IT World
January 13, 2003
Malorye Branca |
Charting a Course After the Genome A quarterly feature looks at the financial numbers in the bio-IT industry. |
Bio-IT World
February 10, 2003
Salvatore Salamone |
Made in Manhattan A talk with the new head of the Computational Biology Center at Memorial Sloan-Kettering. |
Bio-IT World
October 9, 2002
Kevin Davies |
Cracking the 'Druggable Genome' How many potential drug targets are encoded in the human genome? It is a crucial question for every biopharma business. |
